Pharma Focus Asia
KP - Sustainable Packaging Solutions

Replicate Bioscience and Immunomic Therapeutics Form Collaboration to Combat Infectious Diseases and Cancers

Thursday, June 25, 2020

Replicate Bioscience, Inc., a privately-held biopharmaceutical company creating novel treatments to prevent drug resistance in cancers, and Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that the companies have entered into a research and licensing option agreement to combine their platform technologies to combat infectious diseases and cancers.

ITI and Replicate will develop candidates combining ITI’s UNITE technology with Replicate’s scalable self-replicating RNA (SynRGY technology) for COVID-19, HPV, and EBV. Through the collaboration, ITI will be responsible for all development costs and ITI will also invest in Replicate Bioscience. As part of the investment, ITI’s Co-founder and Chief Scientific Officer, Dr. Teri Heiland, will be appointed to Replicate’s Scientific Advisory Board.

“We are excited to partner with Replicate and invest in their seed round as the first strategic shareholder of the company. They have an impressive team with a wealth of expertise in RNA therapeutics and immuno-oncology and we believe that their SynRGY technology is a next-generation solution for combatting drug resistance in cancer,” said Dr. William Hearl, CEO of Immunomic Therapeutics. “Through this collaboration, we look forward to combining SynRGY with our UNITE platform in infectious disease development programs, including those useful in cancers.”

“Ninety-percent of cancer related deaths are a direct result of drug resistance caused by the evolution of the tumor over time. Developing treatments for drug resistance that are deployable at earlier stages of care is a critical unmet need. Alongside their investment, the Immunomic Therapeutics team brings immense value in supporting the development of our internal wholly-owned immuno-oncology candidates. In addition, their team is ideally suited to clinically advancing our joint candidates,” said Dr. Nathaniel Wang, CEO of Replicate Bioscience. “Through this partnership, we are excited to rapidly advance candidates into the clinic for COVID-19 and infectious diseases that lead to the development and progression of various cancers.”

Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelTFS - ODW - The Technology Debate: Single-Use vs. Stainless SteelEquinix accelerated medical research...Asia Healthcare Week 2024CPHI Korea 2024Thermofisher - Antibody Therapeutic PolishingCHEMICAL INDONESIA 20244th Middle East Pharmacoeconomics and Drug Policy Summit 2024INALAB 2024Digital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference
Searching for an end-to-end patient tech solution?